Cargando…
Impulsivity and Its Relationship With Lisdexamfetamine Dimesylate Treatment in Binge Eating Disorder
High trait impulsivity is thought to contribute to the sense of loss of control over eating and impulses to binge eat experienced by those with binge eating disorder (BED). Lisdexamfetamine dimesylate (LDX), a drug approved for treatment of moderate to severe BED, has been shown to decrease impulsiv...
Autores principales: | Griffiths, Kristi R., Aparício, Leonor, Braund, Taylor A., Yang, Jenny, Harvie, Grace, Harris, Anthony, Hay, Phillipa J., Touyz, Stephen, Kohn, Michael R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439192/ https://www.ncbi.nlm.nih.gov/pubmed/34531798 http://dx.doi.org/10.3389/fpsyg.2021.716010 |
Ejemplares similares
-
Understanding the neural mechanisms of lisdexamfetamine dimesylate (LDX) pharmacotherapy in Binge Eating Disorder (BED): a study protocol
por: Griffiths, Kristi R., et al.
Publicado: (2019) -
The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA
por: Ágh, Tamás, et al.
Publicado: (2016) -
The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study
por: Schneider, Elizabeth, et al.
Publicado: (2022) -
Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale
por: Yee, Karen S., et al.
Publicado: (2020) -
A Systematic Review of the Safety of Lisdexamfetamine Dimesylate
por: Coghill, David R., et al.
Publicado: (2014)